LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (OTCBB:IMUC) announced today that Helen Kim has been appointed to the Company’s Board of Directors and has been elected to be Chairperson of the Company’s Product Strategic Committee. Ms. Kim currently serves on the Board of Directors at Sunesis Pharmaceuticals and as the Chief Business Officer of NGM Biopharmaceuticals, a privately held drug discovery company.
